Patient Case Study: Lung Cancer – Reasons For ZOMETA®

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Lung Cancer Patient Case Study – Anthony

Anthony P.

Aged 64 years
Retired auto mechanic
Quit smoking 10 years ago

Page

1 2

As new treatments extend survival, the threat of SREs increases for patients like Anthony

The median survival for patients with advanced lung cancer treated with paclitaxel + carboplatin + bevacizumab is more than 1 year⁴
The median time to first SRE is only 1.2 months after diagnosis of metastasis in patients with lung cancer⁵

Median time to first SRE vs median survival in advanced lung cancer^4,5

ZOMETA®: Median time to first SRE vs. Survival time in lung cancer patients

*Median survival of patients treated with paclitaxel + carboplatin + bevacizumab.

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.